SCHEMBL6000575

SCHEMBL6000575

CCCC(CCC)c1ccc(CN(C)C(=O)c2ccc(-c3csc(CN(CC(=O)O)Cc4ccccc4)n3)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 1/20 0.57
PTPN1 P18031 1/20 0.57
ROCK2 O75116 1/20 0.39
ROCK1 Q13464 1/20 0.39
MMP1 P03956 4/20 0.39
MMP13 P45452 4/20 0.39
HDAC6 Q9UBN7 3/20 0.39
MMP2 P08253 3/20 0.39
MMP9 P14780 3/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC4 P56524 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
LIMK2 P53671 1/20 0.37
GRM1 Q13255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6000801 0.92 PTPN2 (0.57) PTPN2PTPN1MMP1MMP13HDAC6
SCHEMBL5999855 0.88 PTPN2 (0.58) PTPN2PTPN1ROCK2ROCK1MMP1
SCHEMBL6001002 0.88 PTPN2 (0.58) PTPN2PTPN1ROCK2ROCK1MMP1
SCHEMBL6000540 0.88 PTPN2 (0.58) PTPN2PTPN1ROCK2ROCK1MMP1
SCHEMBL5999182 0.87 PTPN2 (0.55) PTPN2PTPN1ROCK2ROCK1MMP1
SCHEMBL6000550 0.86 PTPN2 (0.54) PTPN2PTPN1MMP1MMP13MMP2
SCHEMBL6000679 0.85 PTPN2 (0.54) PTPN2PTPN1HDAC6HDAC2MEN1
SCHEMBL5999110 0.85 PTPN2 (0.76) PTPN2PTPN1MMP1MMP13MMP2
SCHEMBL6001017 0.85 PTPN2 (0.76) PTPN2PTPN1MMP1MMP13MMP2
SCHEMBL6000545 0.84 PTPN2 (0.55) PTPN2PTPN1MMP1MMP13MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-06-08 US claimed
EP-1553091-A1 HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2005-07-13 EP claimed
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-06-08 US disclosed
EP-1553091-A1 HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof PTPN11, PTPN1, PTPN3 PTPN2 11/4885PTPN1 2/4885ROCK2 1672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.